MX2019013095A - Formulaciones farmaceuticas de estatinas y acidos grasos omega-3 para encapsulacion. - Google Patents

Formulaciones farmaceuticas de estatinas y acidos grasos omega-3 para encapsulacion.

Info

Publication number
MX2019013095A
MX2019013095A MX2019013095A MX2019013095A MX2019013095A MX 2019013095 A MX2019013095 A MX 2019013095A MX 2019013095 A MX2019013095 A MX 2019013095A MX 2019013095 A MX2019013095 A MX 2019013095A MX 2019013095 A MX2019013095 A MX 2019013095A
Authority
MX
Mexico
Prior art keywords
phase
omega
fatty acids
dosage form
statins
Prior art date
Application number
MX2019013095A
Other languages
English (en)
Inventor
Okutan Beth
Draper Peter
Draper James
Original Assignee
Accucaps Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accucaps Industries Ltd filed Critical Accucaps Industries Ltd
Publication of MX2019013095A publication Critical patent/MX2019013095A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Una forma de dosificación de gelatina blanda de múltiples fases que comprende por lo menos una forma de dosificación sólida preformada que comprende un compuesto de estatina y por lo menos una fase de relleno líquida que comprende ácidos grasos Omega-3. Las formas de dosificación de gelatina blanda de múltiples fases de la presente invención son especialmente útiles para combinar por lo menos una forma de dosificación sólida y por lo menos una fase líquida para una sola ingestión. La fase sólida, la fase líquida o los recubrimientos además pueden comprender ingredientes farmacéuticos activos, nutracéuticos, suplementos nutricionales, o sustancias terapéuticas, excipientes convencionales o combinaciones de los mismos.
MX2019013095A 2010-06-03 2012-11-29 Formulaciones farmaceuticas de estatinas y acidos grasos omega-3 para encapsulacion. MX2019013095A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2706270A CA2706270C (en) 2010-06-03 2010-06-03 Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation

Publications (1)

Publication Number Publication Date
MX2019013095A true MX2019013095A (es) 2020-01-30

Family

ID=45066009

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012013933A MX369477B (es) 2010-06-03 2011-06-03 Formulaciones farmacéuticas de estatinas y ácidos grasos omega-3 para encapsulación.
MX2019013095A MX2019013095A (es) 2010-06-03 2012-11-29 Formulaciones farmaceuticas de estatinas y acidos grasos omega-3 para encapsulacion.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012013933A MX369477B (es) 2010-06-03 2011-06-03 Formulaciones farmacéuticas de estatinas y ácidos grasos omega-3 para encapsulación.

Country Status (12)

Country Link
US (2) US11975108B2 (es)
EP (2) EP2575787B1 (es)
JP (2) JP5972261B2 (es)
AU (1) AU2011261117B2 (es)
CA (1) CA2706270C (es)
DK (1) DK2575787T3 (es)
ES (1) ES2807498T3 (es)
HU (1) HUE050830T2 (es)
MX (2) MX369477B (es)
PL (1) PL2575787T3 (es)
PT (1) PT2575787T (es)
WO (1) WO2011150505A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014095628A1 (en) * 2012-12-17 2014-06-26 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Oral formulation containing a statin in omega-3 polyunsaturated fatty acids (n-3 pufa)
MX2016004487A (es) 2013-10-30 2016-11-10 Banner Life Sciences Llc Capsulas blandas de capa entérica que constan de ácidos grasos poli insaturados.
US9326965B2 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
WO2015185240A1 (en) 2014-06-04 2015-12-10 Sigma-Tau Industrire Farmaceutiche Riunite S.P.A. Compositions containing simvastatin in omega-3 polyunsaturated fatty acids
US9895333B2 (en) 2014-06-26 2018-02-20 Patheon Softgels Inc. Enhanced bioavailability of polyunsaturated fatty acids
WO2015200563A1 (en) * 2014-06-26 2015-12-30 Banner Life Sciences Llc Enhanced bioavailability of polysaturated fatty acids
WO2016024844A1 (ko) * 2014-08-13 2016-02-18 한국유나이티드제약 주식회사 오메가-3 지방산 에스테르 및 스타틴계 약물을 포함하는 경구용 복합제제
KR101950907B1 (ko) * 2016-02-05 2019-02-21 한국유나이티드제약 주식회사 지용성 약물 및 방유성 기제가 코팅된 고형제제를 포함하는 경구용 복합제제
WO2017171484A1 (ko) * 2016-03-31 2017-10-05 한미약품 주식회사 오메가-3 지방산 또는 이의 에스테르, 및 하이드록시메틸글루타릴 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제
US11547693B2 (en) 2019-07-29 2023-01-10 Matthias Rath Ascorbate in the prevention of statin induced vascular calcification
US10736872B1 (en) * 2019-09-05 2020-08-11 Matthias W. Rath Pharmaceutical mixture to treat statin induced vascular calcification
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
BR102021011153B1 (pt) 2021-06-09 2022-12-27 Fernando Campos Barbosa Composição fitoterápica associada a suplementos polivitamínicos e minerais

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1803440A (en) * 1929-07-25 1931-05-05 Newspaper Mechanical Sales Com Coin control for vending machines
US2775080A (en) 1950-05-26 1956-12-25 American Cyanamid Co Method of forming powder-and-liquid filled capsules
US2711814A (en) * 1953-08-14 1955-06-28 Bartlett And Company Grain Apparatus for cleaning flat bottom grain tanks
US3536074A (en) 1968-03-29 1970-10-27 Alfred Aufhauser Oral administration of a pill,tablet or capsule
US4655027A (en) 1980-11-24 1987-04-07 Chasman Sydney A Method and apparatus for forming capsules
RU2134105C1 (ru) * 1993-06-18 1999-08-10 Смитклайн Бичам Корпорейшн Мягкая желатиновая капсула
NZ520176A (en) * 1997-07-31 2005-02-25 Kos Life Sciences Inc Combinations of HMG-CoA reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night
US6238616B1 (en) 1998-12-14 2001-05-29 Timecaps Inc. Method of manufacturing gelatin capsule containing powder or time release pellets
US6574945B2 (en) 2001-03-21 2003-06-10 Lumitek Llc Method for manufacturing a projectile containing chemiluminescent compounds
DE60219307T2 (de) * 2001-06-12 2008-01-10 Galephar M/F Oral anzuwendende arzneizusammensetzung enthaltend ein statinderivat
WO2004000731A2 (en) 2002-06-25 2003-12-31 Akzo Nobel N.V. Use of cationic layered materials, compositions comprising these materials, and the preparation of cationic layered materials
FR2850275B1 (fr) * 2003-01-24 2005-04-08 Scherer Technologies Inc R P Capsules molles a macher contenant une substance active a gout masque
US20040146537A1 (en) * 2003-01-28 2004-07-29 Ramachandran Radhakrishnan Oily wax matrix suspension formulation comprising pharmacologically active agents
CA2475765A1 (en) * 2003-07-29 2005-01-29 L. Perrigo Company Tablet encapsulating machine
CN1852894A (zh) * 2003-09-17 2006-10-25 沃尼尔·朗伯有限责任公司 [R－(R*, R*)]－2－(4－氟苯基) －β,δ－二羟基－5－(1－甲基乙基) －3－苯基－4－[(苯基氨基)羰基] －1 H－吡咯－1－庚酸的结晶形式
ES2255426B1 (es) * 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
US20070191467A1 (en) * 2004-12-06 2007-08-16 Reliant Pharmaceutical, Inc. Statin and omega-3 fatty acids for lipid therapy
MX2007011031A (es) * 2005-03-08 2008-04-21 Reliant Pharmaceuticals Inc Tratamiento con estatina y acidos grasos omega-3 y un producto de combinacion de los mismos.
US7887852B2 (en) * 2005-06-03 2011-02-15 Soft Gel Technologies, Inc. Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
WO2006136196A1 (en) * 2005-06-21 2006-12-28 V. Mane Fils Gellan seamless breakable capsule and process for manufacturing thereof
CA2634139C (en) * 2005-12-20 2015-06-23 Cenestra, Llc. Omega 3 fatty acid formulations
EP2081550B2 (en) * 2006-03-09 2021-05-26 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
US20070218141A1 (en) * 2006-03-15 2007-09-20 Ashis Kumar Mehta Simvastatin compositions
US20100310650A1 (en) * 2006-06-26 2010-12-09 Roberto Valducci Pharmaceutical composition for the oral administration of omega polyenoic fatty acids and one or more active principles incompatible therewith, and a process for its preparation
US8481084B2 (en) * 2007-05-23 2013-07-09 Amcol International Corporation Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
ITMI20072142A1 (it) * 2007-11-08 2009-05-09 Yervant Zarmanian Composizioni farmaceutiche contenenti statine e derivati di acidi grassi omega-3
US20100285121A1 (en) * 2008-01-10 2010-11-11 Takeda Pharmaceutical Company Limited Capsule Formulation
US20110082119A1 (en) * 2008-06-13 2011-04-07 Takashi Yano Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
US20100062057A1 (en) * 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
GB0818472D0 (en) * 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
CA2706272C (en) 2010-06-03 2020-05-05 Accucaps Industries Limited Multi phase soft gel capsules, apparatus and method thereof

Also Published As

Publication number Publication date
EP3581173A1 (en) 2019-12-18
AU2011261117B2 (en) 2015-08-13
WO2011150505A1 (en) 2011-12-08
CA2706270C (en) 2020-01-07
EP2575787A1 (en) 2013-04-10
HUE050830T2 (hu) 2021-01-28
MX2012013933A (es) 2013-02-11
US20230233472A1 (en) 2023-07-27
US11975108B2 (en) 2024-05-07
CA2706270A1 (en) 2011-12-03
PT2575787T (pt) 2020-07-28
US20130115281A1 (en) 2013-05-09
AU2011261117A1 (en) 2012-12-13
MX369477B (es) 2019-11-08
EP2575787A4 (en) 2013-11-27
DK2575787T3 (da) 2020-08-03
JP5972261B2 (ja) 2016-08-17
JP2013527205A (ja) 2013-06-27
PL2575787T3 (pl) 2020-11-02
ES2807498T3 (es) 2021-02-23
JP2016138143A (ja) 2016-08-04
EP2575787B1 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
MX2019013095A (es) Formulaciones farmaceuticas de estatinas y acidos grasos omega-3 para encapsulacion.
WO2011128635A3 (en) Anti-abuse pharmaceutical compositions
NZ600720A (en) A Seamless Capsule For A Liquid Pharmaceutical Composition
WO2011060945A3 (en) Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases
WO2012013331A3 (en) Capsules of active pharmaceutical ingredients and polyunsaturated fatty acids for the treatment of prostate diseases
MX340591B (es) Formulaciones de liberacion inmediata y formas de dosis de gamma-hidroxibutirato.
BR112012026758A2 (pt) cápsula, método para produzir cápsulas com uma estrutura de núcleo/envoltório, usos de cápsulas com uma estrutura de núcleo/envoltório, e de preparações pulverulentas ou líquidas, e, composição farmacêutica, de cosméticos, preparação de proteção de cultura, alimentação de animal, suplemento alimetar ou nutricional
WO2009098520A3 (en) Composition and method for assisting swallowing
WO2007014124A3 (en) High drug load formulations and dosage forms
WO2012085671A3 (en) Antioxidants in fish oil powder and tablets
WO2011060944A3 (en) Active pharmaceutical ingredient capsules and polyunsaturated fatty acid esters
WO2009118359A3 (en) Capsule for the prevention of cardiovascular diseases
EP3658124A4 (en) COMPOSITIONS FOR INCREASING THE BIOAVAILABILITY OF MEDICINAL PRODUCTS, SUPPLEMENTS AND INGESTED SUBSTANCES
EP3279210A4 (en) Peptide having anticancer activity, and pharmaceutical composition and dietary supplement composition for preventing and treating cancer, both of which contain same as active ingredient
PL3793534T3 (pl) Tabletka doustna do dostarczania składników czynnych do przewodu żołądkowo-jelitowego
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
WO2006109194A3 (en) Chromium-fatty acid compounds and methods of making and using thereof
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
PL1744733T3 (pl) Kompozycje farmaceutyczne zamknięte w miękkich kapsułkach żelowych zawierające stężone składniki czynne
JP2013540133A5 (es)
WO2007120838A3 (en) Rapidly disintegrating solid oral dosage form of liquid dispersions
WO2012064130A3 (ko) 대장 선택성 셀레콕시브 전구체 화합물 및 이를 유효성분으로 함유하는 대장성 질환 치료 또는 예방용 약학조성물
WO2012007758A3 (en) Pharmaceutical formulations
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
DK2091520T3 (da) Oral doseringsform omfattende trisubstituerede glycerol-forbindelser